The American Bar Association Antitrust Law Section’s annual Spring Meeting concluded on April 12. The annual Spring Meeting featured updates from federal, state and international antitrust enforcers and extensive discussion...more
4/15/2024
/ American Bar Association (ABA) ,
Antitrust Provisions ,
Biden Administration ,
Competition ,
Consumer Financial Protection Bureau (CFPB) ,
Department of Justice (DOJ) ,
Enforcement ,
FDIC ,
Federal Trade Commission (FTC) ,
Hart-Scott-Rodino Act ,
Mergers ,
No-Poaching ,
Non-Compete Agreements ,
Robinson-Patman Act ,
Settlement ,
Sherman Act ,
The Clayton Act
The American Bar Association’s Antitrust Law Section held its annual Spring Meeting in Washington, DC, on March 29–31, 2023. The Spring Meeting sessions featured updates from federal, state, and international antitrust...more
4/6/2023
/ Acquisitions ,
American Bar Association (ABA) ,
Antitrust Division ,
Antitrust Investigations ,
CFIUS ,
Consumer Financial Protection Bureau (CFPB) ,
Department of Justice (DOJ) ,
Enforcement Priorities ,
Federal Trade Commission (FTC) ,
Hart-Scott-Rodino Act ,
Healthcare ,
Interlocking Directorate ,
Mergers ,
National Security ,
Pre-Merger Filing Requirements ,
Section 8 ,
The Clayton Act
This week, the American Bar Association’s Antitrust Law Section kicked off its annual Spring Meeting in Washington, DC, which features updates from the antitrust enforcers and substantive discussions on today’s most pressing...more
4/8/2022
/ Acquisitions ,
Antitrust Division ,
Antitrust Litigation ,
Cartels ,
Department of Justice (DOJ) ,
Enforcement ,
Federal Trade Commission (FTC) ,
Hart-Scott-Rodino Act ,
Healthcare ,
Horizontal Merger Guidelines ,
Mergers ,
No-Poaching ,
The Clayton Act ,
Vertical Mergers ,
Wage-Fixing
The US Court of Appeals for the Fourth Circuit revived an antitrust suit alleging that a pharmaceutical manufacturer illegally maintained its monopoly for its innovator drug by precluding competition beyond the expiration...more
4/22/2021
/ Anti-Competitive ,
Antitrust Litigation ,
Appeals ,
Drug Pricing ,
Generic Drugs ,
Manufacturers ,
Monopolization ,
Patents ,
Pharmaceutical Industry ,
Sherman Act ,
Statute of Limitations ,
The Clayton Act